// App-Quantinova.ai

: RBTT-08. EORTC 1709/CCTG CE.8: A PHASE III TRIAL OF MARIZOMIB IN COMBINATION WITH STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY VERSUS STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Researchers

Presenter

  • Martin van den Bent

Principal Investigators

  • Warren Mason

  • Benjamin Winograd

  • Michael Weller

Medical Centers

  • Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • University Hospital Zurich, Zurich, SwitzerlCelgene, Summit, NJ, USA

  • Department of Neurology, University Hospital Zurich, Zurich, Switzerland

Locations

  • Netherlands

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • O-6-methylguanine DNA methyltransferase

Drug/Treatment

  • Temozolomide

  • Marizomib

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Superiority

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03345095

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved